Last week, the FAST-Forward Boost trial completed recruitment to the Early Side Effects Substudy with 345 patients randomised. The study will now be transitioning to the main trial part of the study with a target of 4,830 patients. You can read more about the trial here: www.icr.ac.uk/ff-boost

We support #WorldRTDay and the multiprofession approach to high quality #clinicaltrials leading to improved treatment and outcomes for our patients #WRAD

Want the opportunity to work at the forefront of RT #clinicaltrials? We are hiring! Band 7 Clinical Scientist/Radiographer. 1-year post, renewable subject to funding: www.enherts-tr.nhs.uk/careers/vaca... Deadline 18th August. DM for further information. #medphys #rtt #rtqa

Current vacancies – East and North Hertfordshire NHS Trust

Are you a retired NHS employee? You could join the NHS Retirement Fellowship.

enherts-tr.nhs.uk

Want the opportunity to work at the forefront of RT #clinicaltrials? We are hiring! Band 7 Clinical Scientist/Radiographer. 1-year post, renewable subject to funding: www.enherts-tr.nhs.uk/careers/vaca... Deadline 18th August. DM for further information. #medphys #rtt #rtqa

Current vacancies – East and North Hertfordshire NHS Trust

Are you a retired NHS employee? You could join the NHS Retirement Fellowship.

enherts-tr.nhs.uk

We are looking for two exceptional consultant uro-oncologists to come and join our team in Sutton. Please see further details 👇 www.royalmarsden.nhs.uk/current-vaca...

Want to be part of shaping the future direction of RT research in the UK? An exciting opportunity has arisen to work as a research fellow within the @nihr.bsky.social RTTQA Group, based at Mount Vernon Cancer Centre. For more info please DM us! #radonc #rtqa www.nhsjobs.com/job/UK/Hertf...

Very excited to do the #RTQA for this trial

ICR-CTSU@icr-ctsu.bsky.social · last yr.

FAST-Forward Boost is a national breast radiotherapy trial and is investigating whether people with #BreastCancer can be treated with #Radiotherapy with a tumour bed boost as effectively and safely within 1 week instead of 3 weeks. Read more about the trial here:

Proud to have contributed to this important study #RTQA

ICR-CTSU@icr-ctsu.bsky.social · last yr.

At #ESTRO2025, the 10-year results of the FAST-Forward #ClinicalTrial were presented. The results confirmed 5-year findings showing that treating early stage #BreastCancer with #Radiotherapy to the breast & chest wall over 1-week is as safe and effective as the standard 3-week treatment.

Congratulations to our very own Liz Miles, incredible colleague, mentor & friend on her #ESTRO25 Interdisciplinary Award. A true champion for #collaboration and #RTQA. So well deserved- we could not be prouder!

Congratulations Liz on your interdisciplinary award👏🏽🥳 @rttqa.bsky.social _UK does an incredible job ensuring that #radiotherapy is robust. Fantastic leadership! @nhsengland.bsky.social #ESTRO25

Tightenining dose-volume constraints in oesophageal cancer to ensure best practice and further reduce toxicities. Geraint Lewis (Velindre Cancer Centre and @rttqa.bsky.social) presents modified #SCOPE2 trial constraints incorporated into the #PROTIEUS photon vs proton #clinicaltrial

Dr Murray Brunt presents the excellent 10y results of the FAST-FORWARD #breast cancer trial. A pleasure to have contributed to this practice-changing #clinicaltrial @nihr.bsky.social @icr-ctsu.bsky.social

Rita Simoes presents initial results for deriving dose-volume constraints of the treatment “corridor” in the treatment of limb #sarcoma; with Aisha Miah, Beatrice Seddon and Martin Robinson. UCL CTC and Birmingham CTU #ESTRO25

Regional LN delineation variability in #BrCa RT within the Fast Forward trial. Despite this variability, all mandatory constraints were adhered to. #RTQA plays a central role in providing support & guidance to participating centres www.sciencedirect.com/science/arti...

Regional Lymph Node Delineation variability and its Dosimetric Impact in Breast Cancer Radiotherapy

To quantify the interobserver variability of regional lymph node delineation for breast cancer radiotherapy (RT) and establish whether a relationship …

sciencedirect.com

#NOTCH2025 ✅ Quality Assurance is key in clinical trials, yet often overlooked! Dr. Sarah Gwynne SW Wales Cancer Centre (@rttqa.bsky.social) delivered an outstanding session on RT QA in the SCOPE trial A fantastic deep dive into an essential aspect of oncology research 🎯

Congrats Dr Tree! Proud to have supported the study.

Alison Tree@alison-tree.bsky.social · last yr.

TRAP trial results now out @ijrobp.bsky.social funded by @prostatecanceruk.bsky.social Men oligoprogressing on Abi/Enza for CRPC, nearly 40% progression-free 1 year after SBRT. No significant side effects due to radiotherapy. www.sciencedirect.com/science/arti...

TRAP trial results now out @ijrobp.bsky.social funded by @prostatecanceruk.bsky.social Men oligoprogressing on Abi/Enza for CRPC, nearly 40% progression-free 1 year after SBRT. No significant side effects due to radiotherapy. www.sciencedirect.com/science/arti...

Stereotactic body radiotherapy for oligoprogressive disease in androgen suppressed prostate cancer: Primary endpoint analysis of the TRAP trial

Optimal management of oligoprogressive prostate cancer whilst on androgen receptor pathway inhibitors (ARPi) is not known. The **** trial tests the ro…

sciencedirect.com